Literature DB >> 20197460

Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.

Stella Koutros1, Fredrick R Schumacher, Richard B Hayes, Jing Ma, Wen-Yi Huang, Demetrius Albanes, Federico Canzian, Stephen J Chanock, E David Crawford, W Ryan Diver, Heather Spencer Feigelson, Edward Giovanucci, Christopher A Haiman, Brian E Henderson, David J Hunter, Rudolf Kaaks, Laurence N Kolonel, Peter Kraft, Loïc Le Marchand, Elio Riboli, Afshan Siddiq, Mier J Stampfer, Daniel O Stram, Gilles Thomas, Ruth C Travis, Michael J Thun, Meredith Yeager, Sonja I Berndt.   

Abstract

The phosphatidylinositol 3-kinase (PI3K) pathway regulates various cellular processes, including cellular proliferation and intracellular trafficking, and may affect prostate carcinogenesis. Thus, we explored the association between single-nucleotide polymorphisms (SNP) in PI3K genes and prostate cancer. Pooled data from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium were examined for associations between 89 SNPs in PI3K genes (PIK3C2B, PIK3AP1, PIK3C2A, PIK3CD, and PIK3R3) and prostate cancer risk in 8,309 cases and 9,286 controls. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using logistic regression. SNP rs7556371 in PIK3C2B was significantly associated with prostate cancer risk [OR(per allele), 1.08 (95% CI, 1.03-1.14); P(trend) = 0.0017] after adjustment for multiple testing (P(adj) = 0.024). Simultaneous adjustment of rs7556371 for nearby SNPs strengthened the association [OR(per allele), 1.21 (95% CI, 1.09-1.34); P(trend) = 0.0003]. The adjusted association was stronger for men who were diagnosed before the age of 65 years [OR(per allele), 1.47 (95% CI, 1.20-1.79); P(trend) = 0.0001] or had a family history [OR(per allele) = 1.57 (95% CI, 1.11-2.23); P(trend) = 0.0114], and was strongest in those with both characteristics [OR(per allele) = 2.31 (95% CI, 1.07-5.07), P-interaction = 0.005]. Increased risks were observed among men in the top tertile of circulating insulin-like growth factor-I (IGF-I) levels [OR(per allele) = 1.46 (95% CI, 1.04-2.06); P(trend) = 0.075]. No differences were observed with disease aggressiveness (Gleason grade >or=8 or stage T(3)/T(4) or fatal). In conclusion, we observed a significant association between PIK3C2B and prostate cancer risk, especially for familial, early-onset disease, which may be attributable to IGF-dependent PI3K signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197460      PMCID: PMC2840184          DOI: 10.1158/0008-5472.CAN-09-3575

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Growth factor regulation of the novel class II phosphoinositide 3-kinases.

Authors:  R A Brown; P R Shepherd
Journal:  Biochem Soc Trans       Date:  2001-08       Impact factor: 5.407

2.  Does a family history of prostate cancer result in more aggressive disease?

Authors:  E A Klein; P A Kupelian; J S Witte
Journal:  Prostate Cancer Prostatic Dis       Date:  1998-12       Impact factor: 5.554

3.  A genome-wide association study of global gene expression.

Authors:  Anna L Dixon; Liming Liang; Miriam F Moffatt; Wei Chen; Simon Heath; Kenny C C Wong; Jenny Taylor; Edward Burnett; Ivo Gut; Martin Farrall; G Mark Lathrop; Gonçalo R Abecasis; William O C Cookson
Journal:  Nat Genet       Date:  2007-09-16       Impact factor: 38.330

4.  Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort.

Authors:  Carmen Rodriguez; Stephen J Freedland; Anusila Deka; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12-19       Impact factor: 4.254

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.

Authors:  June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci
Journal:  J Natl Cancer Inst       Date:  2002-07-17       Impact factor: 13.506

Review 7.  Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

8.  IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard B Hayes
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

9.  Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.

Authors:  Liesel M Fitzgerald; Erika M Kwon; Joseph S Koopmeiners; Claudia A Salinas; Janet L Stanford; Elaine A Ostrander
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

Review 10.  Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk.

Authors:  Li Li; Sarah J Plummer; Cheryl L Thompson; Thomas C Tucker; Graham Casey
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

View more
  23 in total

1.  Targeting PI3K in Cancer: Any Good News?

Authors:  Miriam Martini; Elisa Ciraolo; Federico Gulluni; Emilio Hirsch
Journal:  Front Oncol       Date:  2013-05-08       Impact factor: 6.244

Review 2.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

3.  The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression.

Authors:  Norbert Varga; Johanna Mózes; Helen Keegan; Christine White; Lynne Kelly; Loretto Pilkington; Márta Benczik; Schaff Zsuzsanna; Gábor Sobel; Róbert Koiss; Edit Babarczi; Miklos Nyíri; Laura Kovács; Sebe Attila; Borbála Kaltenecker; Adrienn Géresi; Adrienn Kocsis; John O'Leary; Cara M Martin; Csaba Jeney
Journal:  Pathol Oncol Res       Date:  2016-08-06       Impact factor: 3.201

4.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

5.  Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2β) isoform contributes to neuroblastoma tumorigenesis.

Authors:  Angela Russo; Mustafa Nazir Okur; Maarten Bosland; John P O'Bryan
Journal:  Cancer Lett       Date:  2015-01-23       Impact factor: 8.679

6.  Comprehensive gene expression analysis reveals multiple signal pathways associated with prostate cancer.

Authors:  Yi Liu; Hua Song; Jing Pan; Jing Zhao
Journal:  J Appl Genet       Date:  2013-10-24       Impact factor: 3.240

7.  Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Authors:  Erika M Kwon; Claudia A Salinas; Suzanne Kolb; Rong Fu; Ziding Feng; Janet L Stanford; Elaine A Ostrander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-23       Impact factor: 4.254

8.  Identification of the gene expression changes and gene regulatory aspects in ELF3 mutant bladder cancer.

Authors:  Perihan Yagmur Guneri-Sozeri; Serap Erkek-Ozhan
Journal:  Mol Biol Rep       Date:  2022-02-24       Impact factor: 2.316

9.  PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.

Authors:  Yuan Shi; Xiaodong Gao; Qin Hu; Xiaojing Li; Jianfang Xu; Shaohua Lu; Yalan Liu; Chen Xu; Dongxian Jiang; Jiaqian Lin; Anwei Xue; Yunshan Tan; Kuntang Shen; Yingyong Hou
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

10.  Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Authors:  Rosalind A Eeles; Ali Amin Al Olama; Sara Benlloch; Edward J Saunders; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Maya Ghoussaini; Craig Luccarini; Joe Dennis; Sarah Jugurnauth-Little; Tokhir Dadaev; David E Neal; Freddie C Hamdy; Jenny L Donovan; Ken Muir; Graham G Giles; Gianluca Severi; Fredrik Wiklund; Henrik Gronberg; Christopher A Haiman; Fredrick Schumacher; Brian E Henderson; Loic Le Marchand; Sara Lindstrom; Peter Kraft; David J Hunter; Susan Gapstur; Stephen J Chanock; Sonja I Berndt; Demetrius Albanes; Gerald Andriole; Johanna Schleutker; Maren Weischer; Federico Canzian; Elio Riboli; Tim J Key; Ruth C Travis; Daniele Campa; Sue A Ingles; Esther M John; Richard B Hayes; Paul D P Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Elaine A Ostrander; Lisa B Signorello; Stephen N Thibodeau; Dan Schaid; Christiane Maier; Walther Vogel; Adam S Kibel; Cezary Cybulski; Jan Lubinski; Lisa Cannon-Albright; Hermann Brenner; Jong Y Park; Radka Kaneva; Jyotsna Batra; Amanda B Spurdle; Judith A Clements; Manuel R Teixeira; Ed Dicks; Andrew Lee; Alison M Dunning; Caroline Baynes; Don Conroy; Melanie J Maranian; Shahana Ahmed; Koveela Govindasami; Michelle Guy; Rosemary A Wilkinson; Emma J Sawyer; Angela Morgan; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas J Van As; Christopher J Woodhouse; Alan Thompson; Tim Dudderidge; Chris Ogden; Colin S Cooper; Artitaya Lophatananon; Angela Cox; Melissa C Southey; John L Hopper; Dallas R English; Markus Aly; Jan Adolfsson; Jiangfeng Xu; Siqun L Zheng; Meredith Yeager; Rudolf Kaaks; W Ryan Diver; Mia M Gaudet; Mariana C Stern; Roman Corral; Amit D Joshi; Ahva Shahabi; Tiina Wahlfors; Teuvo L J Tammela; Anssi Auvinen; Jarmo Virtamo; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Sune F Nielsen; Stig E Bojesen; Afshan Siddiq; Liesel M Fitzgerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; William J Blot; Wei Zheng; Qiuyin Cai; Shannon K McDonnell; Antje E Rinckleb; Bettina Drake; Graham Colditz; Dominika Wokolorczyk; Robert A Stephenson; Craig Teerlink; Heiko Muller; Dietrich Rothenbacher; Thomas A Sellers; Hui-Yi Lin; Chavdar Slavov; Vanio Mitev; Felicity Lose; Srilakshmi Srinivasan; Sofia Maia; Paula Paulo; Ethan Lange; Kathleen A Cooney; Antonis C Antoniou; Daniel Vincent; François Bacot; Daniel C Tessier; Zsofia Kote-Jarai; Douglas F Easton
Journal:  Nat Genet       Date:  2013-04       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.